Dermatitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dermatitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the effectiveness of NAV-240 in adults with moderate-to-severe hidradenitis suppurativa https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-nav-240-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:09:39 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-nav-240-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study investigates a treatment for individuals with Hidradenitis Suppurativa, a chronic skin condition that causes painful bumps, abscesses (painful, pus-filled lumps), and draining tunnels (channels under the skin that leak fluid) under the skin. The research aims to determine if the experimental drug NAV-240 is more effective than a placebo in managing this condition.

Participants in this clinical trial will be randomly assigned to receive either NAV-240 or a placebo consisting of sodium chloride. The medication will be administered through an intravenous method, which means it is delivered directly into a vein using a solution for infusion. To ensure the results are reliable, the study is double-blind, meaning neither the participants nor the researchers know which treatment is being given during the course of the study.

]]> Study on Ustekinumab and Drug Combination for Patients with Severe, Resistant Inflammatory Disease https://clinicaltrials.eu/trial/study-on-ustekinumab-and-drug-combination-for-patients-with-severe-resistant-inflammatory-disease/ Wed, 29 Apr 2026 14:59:45 +0000 https://clinicaltrials.eu/trial/study-on-ustekinumab-and-drug-combination-for-patients-with-severe-resistant-inflammatory-disease/ This clinical trial is focused on studying treatments for patients with a severe and resistant inflammatory disease that affects multiple organs. The disease is not classified under any specific category and can impact areas such as the skin, lymph nodes, blood-forming system, joints, digestive tract, eyes, nerves, brain, respiratory system, heart, blood vessels, urinary system, and muscles. The study aims to evaluate the effectiveness of personalized treatments that are chosen based on a detailed analysis of the patient’s specific inflammatory pathways.

The treatments being tested in this study include several medications: Ustekinumab, Secukinumab, Adalimumab, Anakinra, Rituximab, and Tocilizumab. These medications are administered through injections, either under the skin or directly into the bloodstream. Each medication works by targeting specific parts of the immune system to reduce inflammation and improve symptoms.

Participants in the study will receive one of these treatments, or a placebo, over a period of several months. The main goal is to see if there is an improvement in the disease’s activity, particularly in the skin and other affected areas. The study will monitor changes in symptoms and biological markers of inflammation to determine the effectiveness of the treatments. The results will help in understanding how these targeted therapies can benefit patients with complex inflammatory diseases.

]]> Study on Dupilumab for Treating Nummular Eczema in Patients https://clinicaltrials.eu/trial/study-on-dupilumab-for-treating-nummular-eczema-in-patients/ Wed, 29 Apr 2026 14:22:44 +0000 https://clinicaltrials.eu/trial/study-on-dupilumab-for-treating-nummular-eczema-in-patients/ This clinical trial is focused on studying the effects of a medication called Dupilumab on a skin condition known as nummular eczema. Nummular eczema is a type of eczema that causes round, itchy patches on the skin. The medication being tested, Dupilumab, is given as a solution for injection using a pre-filled syringe. It is designed to help reduce the symptoms of eczema by targeting specific proteins in the body that cause inflammation.

The purpose of this study is to evaluate how effective Dupilumab is in treating nummular eczema. Participants in the study will receive either Dupilumab or a placebo, which is a substance with no active medication. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results. The study will last for a period of 16 weeks, during which participants will receive regular injections and have their skin condition monitored by healthcare professionals.

Throughout the study, various aspects of the participants’ skin condition will be assessed, including changes in the severity of eczema and overall skin health. The study will also monitor any side effects or adverse reactions to Dupilumab. By the end of the study, researchers hope to determine whether Dupilumab is a safe and effective treatment option for individuals with nummular eczema.

]]>